Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318679 · ClinicalTrials.gov registry record
Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 88
- Enrollment target
NCT03318679 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 88 participants.
The verdict
NCT03318679 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
Hyperglycemia is present in 50 percent of patients with acute ischemic stroke. Patients with hyperglycemia have higher in hospital, 30 and 90 day mortality and morbidity. Sixty percent of these patients have some form of diabetic syndrome, known or unknown. Remaining 40% of patients are not diabetic. Contrary to logic patients with non diabetic hyperglycemia (NDH) have statistically higher morbidity and mortality compared to the diabetic hyperglycemia (DH) cohort. So far multiple treatment trials (THIS, GRASP, GIST-UK, SHINE ongoing) with differing treatment goals have shown no clear benefit, however no obvious distinction was made along the diabetic and non-diabetic hyperglycemic groups. If hyperglycemia in the acute phase was the only culprit in worsening the injury, then there should be no difference in the outcomes for DH and NDH. Existing data implies that the two categories are two distinct physiological entities that are thus not amenable to same treatment. Stating it simply NDH is not an insulin deficient state where as DH is. Alternative possibility is that body and Neurons are accustomed to high sugars in diabetics and thus can tolerate higher sugars better during ischemic stroke compared to non diabetics. The overarching hypothesis is that reducing blood sugars in NDH increases stroke volume and thus consequently worsens outcome.
Interventions
- OTHER No intervention is planned.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2020-12-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318679
The ClinicalTrials.gov registry entry for NCT03318679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is planned. is the first listed.
NCT03318679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318679 about?
NCT03318679 is a clinical study titled "Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia". Hyperglycemia is present in 50 percent of patients with acute ischemic stroke. Patients with hyperglycemia have higher in hospital, 30 and 90 day mortality and morbidity. Sixty percent of these patients have some form of diabetic syndrome, known or unknown. Remaining 40% of patients are not diabetic...
What is the current status of trial NCT03318679?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2017-11-01. Estimated completion is 2020-12-25.
What interventions are being tested in trial NCT03318679?
The interventions under investigation include: No intervention is planned. (OTHER).
Who is sponsoring clinical trial NCT03318679?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.